7 completed, 2 active not recruiting, 1 available, 1 not yet recruiting. 6 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Pulmonary Alveolar Proteinosis, Acquired: new trials by email Literature Review of Pulmonary Alveolar Proteinosis, Acquired trials Research Report on Pulmonary Alveolar Proteinosis, Acquired
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of hBMMSC Injection in Patients With aPAP The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid) - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Not yet recruiting | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | 70 | 2026-10-30 | 2026-10-22 |
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Recruiting | Savara Inc. | 5 | 2025-10-22 | 2026-02-19 |
| Study of Human Bone Marrow Mesenchymal Stem Cells in APAP human Bone Marrow Mesenchymal Stem Cell (hBMMSC) - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Active not recruiting | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | 10 | 2023-12-25 | 2025-03-24 |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Molgramostim, Placebo, Molgramostim Open-label - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Active not recruiting | Savara Inc. | 164 | 2021-05-19 | 2026-08-26 |
| The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis | Completed | Children's Hospital Medical Center, Cincinnati | 29 | 2018-04-19 | 2021-06-24 | |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Terminated | Savara Inc. | 60 | 2018-04-16 | 2024-07-03 |
| Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis Pioglitazone - Autoimmune Pulmonary Alveolar Proteinosis | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 3 | 2017-08-17 | 2020-01-18 |
| Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis Sargramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 10 | 2017-07-13 | 2021-08-03 |
| Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan Sargramostim, Placebo - Pulmonary Alveolar Proteinosis, Autoimmune | Phase 2 | Completed | Niigata University Medical & Dental Hospital | 78 | 2016-09-01 | 2019-02-07 |
| SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study Sargramostim - Pulmonary Alveolar Proteinosis, Autoimmune | Phase 1 | Completed | Niigata University Medical & Dental Hospital | 14 | 2016-05-01 | 2017-12-18 |
| Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis Molgramostim, Placebo, PARI eFlow nebulizer system - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Completed | Savara Inc. | 139 | 2016-03-21 | 2023-04-12 |
| Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP) GM-CSF - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Unknown | Peking Union Medical College Hospital | 42 | 2014-08-01 | 2014-09-17 |
| Inhaled GM-CSF Therapy of Autoimmune PAP Baseline WLL, Sargramostim, Rescue WLL - Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 18 | 2009-07-01 | 2024-07-12 |
| Molgramostim Nebulizer Solution Expanded Access Program Protocol Molgramostim nebulizer solution - Autoimmune Pulmonary Alveolar Proteinosis | Available | Savara Inc. | 2026-10-13 |
Pulmonary Alveolar Proteinosis (2)
Lung Diseases (2) · Respiratory Tract Diseases (2)
molgramostim (4) · regramostim (4) · sargramostim (4) · Colony-Stimulating Factors (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3) · Crystalloid Solutions (1) · Injections (1) · Macrophage Colony-Stimulating Factor (1) · Pioglitazone (1) · Ringer's Lactate (1)
Savara Inc. (5) · Children's Hospital Medical Center, Cincinnati (3) · Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. (2) · Niigata University Medical & Dental Hospital (2) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Peking Union Medical College Hospital (1)
United States (6) · Germany (4) · Italy (4) · Japan (4) · China (3) · France (3) · Greece (3) · Netherlands (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Israel (2) · Portugal (2) · Russia (2)
Bruce Trapnell, MD (3) · Bruce Trapnell (1) · Cliff Morgan, MD (1) · Francesca Mariani, MD (1) · Francesco Bonella, Prof. (1) · Kai-Feng Xu, M.D. (1) · Matthias Griese, MD, (1)
PMID 31483963, PMID 32615994, PMID 40834301
2015 (1), 2017 (1), U54HL127672 (1), UL1TR001425 (1)